Aethlon Medical - 15 Year Stock Price History | AEMD

Historical daily share price chart and data for Aethlon Medical since 2011 adjusted for splits and dividends. The latest closing stock price for Aethlon Medical as of September 18, 2026 is 6.31.
  • The all-time high Aethlon Medical stock closing price was 1000000.00 on November 17, 2014.
  • The Aethlon Medical 52-week high stock price is 41.35, which is 555.3% above the current share price.
  • The Aethlon Medical 52-week low stock price is 1.41, which is 77.7% below the current share price.
  • The average Aethlon Medical stock price for the last 52 weeks is 13.02.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Aethlon Medical Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2026 8.3689 14.1000 16.4000 1.4300 6.3100 -54.44%
2025 109.8415 320.0000 362.3200 12.4000 13.8500 -95.97%
2024 355.9668 866.0000 872.0000 104.0000 344.0000 -60.73%
2023 1332.4950 1143.6000 2799.6000 568.0000 876.0000 -20.48%
2022 4184.0143 7840.0000 7960.0000 992.0000 1101.6000 -85.19%
2021 12366.1905 10080.0000 43160.0000 6160.0000 7440.0000 -24.70%
2020 6761.8387 5000.0000 17360.0000 2064.0000 9880.0000 156.49%
2019 32952.3710 94800.1000 94800.1000 3343.2000 3852.0000 -96.13%
2018 77214.6048 69600.0000 114000.0000 56010.0000 99600.1000 46.90%
2017 131967.1151 241080.0000 285000.0000 48060.0000 67800.0000 -73.10%
2016 322648.7619 378000.0000 462000.0000 246600.0000 252000.0000 -38.14%
2015 535345.2262 1000000.0000 1000000.0000 144000.0000 407400.0000 -49.23%
2014 579376.6032 540000.0000 1000000.0000 307500.0000 802500.0000 57.35%
2013 369867.8571 225000.0000 795000.0000 213600.0000 510000.0000 148.54%
2012 263247.6000 180000.0000 435000.0000 154500.0000 205200.0000 27.85%
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.004B $0.000B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $338.303B 20.22
Cigna Group (CI) United States $72.740B 8.74
Humana (HUM) United States $46.377B 22.45
Centene (CNC) United States $32.164B 12.55
Molina Healthcare (MOH) United States $10.481B 68.06
Select Medical Holdings (SEM) United States $2.046B 15.43
Joint (JYNT) United States $0.119B 56.27